Montelukast Intermediate Market worth over USD 4,794.76 thousand by 2023 | CAGR 4.34%
Global Montelukast Intermediate Market is expected to grow at CAGR of 4.34% to reach USD 4,794.76 thousand till 2023.
The Global Montelukast Intermediate Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2017 to 2023. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2017 to 2023.
We can provide sample pages for a better understanding of this report.
Request Sample of This Report @ http://www.amecoresearch.com/sample/12949
Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the Global Montelukast Intermediate Market.
The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market.
The market is studied for regions such as North America (U.S., and Canada), Europe (U.K., Germany, France, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East amp; Africa (GCC, South Africa, and Rest of Middle East amp; Africa).
What is the market size in 2018 and the growth rate of the Global Montelukast Intermediate Market?
What is the market drivers, restrains, opportunities governing the Global Montelukast Intermediate Market?
Which are the largest and the fastest growing segments in the Global Montelukast Intermediate Market?
Who are the key players operating in the market and their market position?
What is the pipeline scenario, drug pricing analysis and technological development in the market?
View Detail Report With Complete Table Of Content@ http://www.amecoresearch.com/market-report/montelukast-intermediate-market-12949
Global Montelukast Intermediate Market: Information by Application (Asthma, Allergic Rhinitis, Bronchospasm and Urticaria) - Forecast till 2023
The Global Montelukast Intermediate Market is expected to grow at CAGR of 4.34% to reach USD 4,794.76 thousand till 2023. Montelukast is a leukotriene receptor antagonist (LTRA) used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma. In addition, montelukast is indicated for the treatment of seasonal and perennial allergic rhinitis. Key factors driving the market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration along with the increasing presence of generics. On the contrary, the presence of stringent regulatory policies and the high cost of manufacturing building blocks for active pharmaceutical ingredients are likely to hinder the market growth during the forecast period.
Factors characterizing the market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from API manufacturers, and montelukast patent expiration along with the increasing presence of generics. In 2016, asthma ranked twenty third (global) and thirty-first (in low- and middle-income countries mdash; LMICs) among the leading causes of premature mortality (YLL). The World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are lost and 250,000 asthma deaths are reported worldwide every year.
Montelukast Intermediate Market is expected to grow at CAGR of 4.34% to reach USD 4,794.76 thousand till 2023
The Global Montelukast Intermediate Market in the Americas is segmented into North America and Latin America.
North America is expected to dominate the market. The market growth in this region is mainly due to the presence of giant pharmaceutical companies and sophisticated healthcare infrastructure and the rising prevalence of asthma and allergic rhinitis in the US and Canada. One in 13 people is living with asthma and is more common in adult women than adult men. Around six million children under the age of 18 have asthma being more common in children than adults. Therefore, the increasing burden of asthma is fueling the demand for montelukast and is assisting in market growth.
Europe currently holds a significant share in the global Montelukast Intermediate market. The factors responsible for the market growth in this region are poor air quality due to high fuel emission is increasing the incidence of asthma, allergy, and chronic obstructive pulmonary disease (COPD) in the UK, Germany, and France. The European Respiratory Society reported that, currently, about 30 Million children and adults less than 45 years old have asthma within the UK and Ireland have some of the highest rates of asthma in the world. In Germany, there are an estimated 4 Million asthmatics. In addition, an article published in the NCBI journal stated that the prevalence of allergic diseases in Europe is high.
Asia-Pacific is expected to represent a promising outlook over the forecast period due to the growing geriatric population along with the rising prevalence of respiratory diseases. According to the WHO, currently, there are about 3 Million asthmatics in Japan of whom 7% have severe, and 30% have moderate asthma. In Australia, one child out of six under the age of 16 is affected by asthma, while, India has an estimated 15 to 20 Million.
The Middle East and Africa market are projected to hold the least share in the global Montelukast Intermediate market. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and others.
Global Montelukast Intermediate Market, by Application
Global Montelukast Intermediate Market, by Region
Rest of Europe
Rest of Asia-Pacific
Rest of Latin America
Middle East amp; Africa
Available Additional Customizations
Montelukast API Manufacturer
Academic and Research Institutes
Pharmaceutical Raw Materials Suppliers
Montelukast Intermediate Manufacturers
Market Research and Consulting Firms
Table Of Contents
Montelukast Intermediate Market Global Research Report - Forecast till 2023
1 Executive Summary
2 Market Introduction
3 Research Methodology
4 Market Dynamics
5 Market Factor Analysis
6 Global Montelukast Intermediate Market, By Application
7 Global Montelukast Intermediate Market, by Region
8 Competitive Landscape
9 Company Profiles
Quick Buy This Premium Report From Here: http://www.amecoresearch.com/buy/12949
Ameco Research is the one spot destination for all your research needs. Ameco Research holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.
Email: firstname.lastname@example.org | +1 407 915 4157